Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Container Defect Prompts Recall of Albuterol Inhalers

The recall affects Albuterol Sulfate Inhalation Aerosol, 90mcg, specifically batches manufactured in November 2021.

Pharmaceutical company Cipla has initiated a recall of six specific batches of Albuterol Sulfate Inhalation Aerosol due to a defect in the container. This decision was reached after the discovery of a leakage through the inhaler valve in one of the batches. The aerosol is vital for the treatment of acute asthma exacerbations, and the defect could lead to life-threatening consequences, although no adverse events have been reported thus far.

Key Points:

  • Six batches have been recalled, with batch numbers including IB20045, IB20055, IB20056, IB20057, IB20059, and IB20072, all expiring in November 2023.
  • A leakage was observed in one inhaler in batch number IB20056, leading to the recall from an abundance of caution.
  • The defect may prevent the recommended dose from being delivered, potentially resulting in serious consequences.

Additional Points:

  • Replacement inhalers should be obtained by consumers from the affected batches.
  • Adverse events can be reported to the FDA’s MedWatch program.
  • Further information is available through Cipla’s customer service via phone or email.


  • This recall serves as a precautionary measure to prevent any potential harm that might arise from the container defect, and prompt action is required to ensure patient safety.

Allergy & Immunology Latest Posts

Did You Know?
According to the World Health Organization, asthma affects approximately 339 million people globally and causes around 417,000 deaths annually.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form